This Moderna Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Morgan Stanley analyst Craig Hettenbach downgraded the rating for Hims & Hers Health, Inc. HIMS from Overweight to Equal-Weight and raised the price target from $42 to $60. Hims & Hers Health shares closed at $60.47 on Friday. See how other analysts view this stock.
Deutsche Bank analyst James Shin downgraded the rating for Merck & Co., Inc. MRK from Buy to Hold and lowered the price target from $128 to $105. Merck shares closed at $83.01 on Friday. See how other analysts view this stock.
Wolfe Research analyst Alex Zukin downgraded Datadog, Inc. DDOG from Outperform to Peer Perform. Datadog shares closed at $131.01 on Friday. See how other analysts view this stock.
Barclays analyst Gena Wang downgraded the rating for Moderna Inc MRNA from Overweight to Equal-Weight and lowered the price target from $111 to $45. Moderna shares closed at $32.99 on Friday. See how other analysts view this stock.
Ladenburg Thalmann analyst Paul Fremont downgraded Portland General Electric Co POR from Buy to Neutral. Portland Gen Electric shares closed at $41.64 on Friday. See how other analysts view this stock.